<\/strong><\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1439", "label" : {"_value" : "Biography information for Norman Lamb"}
}
, "answeringMemberConstituency" : {"_value" : "North Norfolk"}
, "answeringMemberPrinted" : {"_value" : "Norman Lamb"}
, "dateOfAnswer" : {"_value" : "2014-12-10", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-12-10T17:00:48.83Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-12-05", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Neurology"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what progress his Department has made in implementing the recommendations of the Public Accounts Committe report, Services for people with neurological conditions, published on 16 March 2012; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4125", "label" : {"_value" : "Biography information for Catherine McKinnell"}
}
, "tablingMemberConstituency" : {"_value" : "Newcastle upon Tyne North"}
, "tablingMemberPrinted" : [{"_value" : "Catherine McKinnell"}
], "uin" : "217478"}
, {"_about" : "http://data.parliament.uk/resources/167775", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/167775/answer", "answerText" : {"_value" : "
A table is attached showing the number of patient safety incidents involving Parkinson\u2019s disease and medicines used to treat Parkinson\u2019s disease, which resulted in low harm, moderate harm and severe harm that were reported to the National Reporting and Learning System between July and November 2014, together with the reporting organisation that reported each such incident.<\/p>
<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/3932", "label" : {"_value" : "Biography information for Dr Dan Poulter"}
}
, "answeringMemberConstituency" : {"_value" : "Central Suffolk and North Ipswich"}
, "answeringMemberPrinted" : {"_value" : "Dr Daniel Poulter"}
, "attachment" : {"_about" : "http://data.parliament.uk/resources/167775/answer/attachment/1", "fileName" : {"_value" : "Patient safety incidents- Parkinson's disease July-Nov 2014.docx"}
, "title" : "Patient safety incidents- Parkinson's Disease"}
, "dateOfAnswer" : {"_value" : "2014-12-08", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-12-08T17:20:01.7Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-12-03", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Parkinson's Disease: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, how many incidents involving Parkinson's disease and medicines used to treat Parkinson's disease resulting in (a) low, (b) moderate and (c) severe harm were reported to the National Reporting and Learning System between July and November 2014; and which reporting organisation reported each such incident.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4125", "label" : {"_value" : "Biography information for Catherine McKinnell"}
}
, "tablingMemberConstituency" : {"_value" : "Newcastle upon Tyne North"}
, "tablingMemberPrinted" : [{"_value" : "Catherine McKinnell"}
], "uin" : "216992"}
, {"_about" : "http://data.parliament.uk/resources/167496", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/167496/answer", "answerText" : {"_value" : "
We have had no such discussions with hospital doctors and general practitioners. Clinicians can already prescribe off-patent drugs and these are widely used in the National Health Service but we are in the process of setting up a round-table discussion with key stakeholders, and are discussing suitable dates with them. Current prescribing arrangements allow clinicians to prescribe such drugs off-label and off-license when it best meets their patients individual clinical needs.<\/p>
<\/p>
The majority of significant new drugs are referred to the National Institute for Health and Care Excellence (NICE) technology appraisal work programme. NHS commissioners are required to fund drugs and treatments recommended by NICE technology appraisal guidance. Other NICE guidance, including clinical guidelines, may address the use of off-patent drugs for treating particular conditions and we expect clinicians and commissioners to take account of this guidance.<\/p>
<\/p>
<\/p>
<\/p>
The Government has recently launched an external review of the pathways for the development, assessment, and adoption of innovative medicines and medical technology to consider how to speed up access for NHS patients to cost-effective new diagnostics, medicines and devices.<\/p>
<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2014-12-05", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-12-05T13:09:58.147Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-12-02", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Drugs: Licensing"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, pursuant to the contribution by the Parliamentary Under Secretary of State for Health on the Off-patent Drugs Bill of 7 November 2014, columns 1114-1118, what discussions he has had with hospitals and GPs on changing clinical pathways to reflect the latest evidence to improve the uptake of effective off-patent drugs; what steps he has taken to set up a round-table discussion of these issues with NHS England and the National Institute for Health and Care Excellence (NICE); when this discussion will take place; and what steps he has taken to accelerate the uptake of (a) off-patent drugs and (b) innovative medicines through NICE guidance.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4125", "label" : {"_value" : "Biography information for Catherine McKinnell"}
}
, "tablingMemberConstituency" : {"_value" : "Newcastle upon Tyne North"}
, "tablingMemberPrinted" : [{"_value" : "Catherine McKinnell"}
], "uin" : "216943"}
, {"_about" : "http://data.parliament.uk/resources/167535", "AnsweringBody" : [{"_value" : "Department for International Development"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/167535/answer", "answerText" : {"_value" : "
The UK\u2019s investment into the CP3 Asia Fund, named \u2018Asia Climate Partners\u2019, is a Cayman Islands based Limited Partnership. The UK\u2019s investment into the IFC Catalyst Fund is through a Scottish limited partnership. The tax jurisdiction is therefore in the Cayman Islands for Asia Climate Partners, and in Scotland for the Catalyst Fund. There are no fees charged by either limited partnership. These jurisdictions were chosen because they comply with the OECD Global Forum on Transparency and Exchange of Information for Tax Purposes.<\/p>
<\/p>
The IFC Catalyst Fund reached first close in November 2012 and the Asia Climate Partners reached first close in November 2014.<\/p>
<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/55", "label" : {"_value" : "Biography information for Sir Desmond Swayne"}
}
, "answeringMemberConstituency" : {"_value" : "New Forest West"}
, "answeringMemberPrinted" : {"_value" : "Mr Desmond Swayne"}
, "dateOfAnswer" : {"_value" : "2014-12-05", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "216944"}
, {"_value" : "216946"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-12-05T14:08:15.163Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "20"}
, "answeringDeptShortName" : {"_value" : "International Development"}
, "answeringDeptSortName" : {"_value" : "International Development"}
, "date" : {"_value" : "2014-12-02", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "International Climate Fund"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for International Development, with reference to the intervention statement for the Climate Public Private Partnership (CP3) Platform, which private equity firm manages the Scottish Limited Partnership for the UK's investment in the CP3 Asia Fund through this Scottish Limited Partnership; and what the cost is of the fees charged by the Scottish Limited Partnership.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4125", "label" : {"_value" : "Biography information for Catherine McKinnell"}
}
, "tablingMemberConstituency" : {"_value" : "Newcastle upon Tyne North"}
, "tablingMemberPrinted" : [{"_value" : "Catherine McKinnell"}
], "uin" : "216945"}
, {"_about" : "http://data.parliament.uk/resources/167536", "AnsweringBody" : [{"_value" : "Department for International Development"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/167536/answer", "answerText" : {"_value" : "
The UK\u2019s investment into the CP3 Asia Fund, named \u2018Asia Climate Partners\u2019, is a Cayman Islands based Limited Partnership. The UK\u2019s investment into the IFC Catalyst Fund is through a Scottish limited partnership. The tax jurisdiction is therefore in the Cayman Islands for Asia Climate Partners, and in Scotland for the Catalyst Fund. There are no fees charged by either limited partnership. These jurisdictions were chosen because they comply with the OECD Global Forum on Transparency and Exchange of Information for Tax Purposes.<\/p>
<\/p>
The IFC Catalyst Fund reached first close in November 2012 and the Asia Climate Partners reached first close in November 2014.<\/p>
<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/55", "label" : {"_value" : "Biography information for Sir Desmond Swayne"}
}
, "answeringMemberConstituency" : {"_value" : "New Forest West"}
, "answeringMemberPrinted" : {"_value" : "Mr Desmond Swayne"}
, "dateOfAnswer" : {"_value" : "2014-12-05", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "216944"}
, {"_value" : "216945"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-12-05T14:08:15.243Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "20"}
, "answeringDeptShortName" : {"_value" : "International Development"}
, "answeringDeptSortName" : {"_value" : "International Development"}
, "date" : {"_value" : "2014-12-02", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "International Climate Fund"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for International Development, what the tax jurisdiction is for the Climate Public Private Partnership (CP3) Asia Fund and (b) International Finance Corporation Catalyst Fund.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4125", "label" : {"_value" : "Biography information for Catherine McKinnell"}
}
, "tablingMemberConstituency" : {"_value" : "Newcastle upon Tyne North"}
, "tablingMemberPrinted" : [{"_value" : "Catherine McKinnell"}
], "uin" : "216946"}
, {"_about" : "http://data.parliament.uk/resources/167538", "AnsweringBody" : [{"_value" : "Department for International Development"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/167538/answer", "answerText" : {"_value" : "
The UK\u2019s investment into the CP3 Asia Fund, named \u2018Asia Climate Partners\u2019, is a Cayman Islands based Limited Partnership. The UK\u2019s investment into the IFC Catalyst Fund is through a Scottish limited partnership. The tax jurisdiction is therefore in the Cayman Islands for Asia Climate Partners, and in Scotland for the Catalyst Fund. There are no fees charged by either limited partnership. These jurisdictions were chosen because they comply with the OECD Global Forum on Transparency and Exchange of Information for Tax Purposes.<\/p>
<\/p>
The IFC Catalyst Fund reached first close in November 2012 and the Asia Climate Partners reached first close in November 2014.<\/p>
<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/55", "label" : {"_value" : "Biography information for Sir Desmond Swayne"}
}
, "answeringMemberConstituency" : {"_value" : "New Forest West"}
, "answeringMemberPrinted" : {"_value" : "Mr Desmond Swayne"}
, "dateOfAnswer" : {"_value" : "2014-12-05", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "216945"}
, {"_value" : "216946"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-12-05T14:08:15.037Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "20"}
, "answeringDeptShortName" : {"_value" : "International Development"}
, "answeringDeptSortName" : {"_value" : "International Development"}
, "date" : {"_value" : "2014-12-02", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "International Climate Fund"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for International Development, with reference to intervention statement for the Climate Public Private Partnership (CP3) Platform, for what reason the UK's investment in the CP3 Asia Fund is made via a Scottish Limited Partnership.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4125", "label" : {"_value" : "Biography information for Catherine McKinnell"}
}
, "tablingMemberConstituency" : {"_value" : "Newcastle upon Tyne North"}
, "tablingMemberPrinted" : [{"_value" : "Catherine McKinnell"}
], "uin" : "216944"}
], "itemsPerPage" : 10, "next" : "https://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography+information+for+Catherine+McKinnell&_page=1&max-ddpCreated=2014-12-16T00%3A42%3A47.573Z", "page" : 0, "startIndex" : 1, "totalResults" : 90, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}